READ-ONLY DIGITIZATION RESULT
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Gastric Cancer · 2024-Nov · PMID 39162872
Panel Central质量警告待 EXE 对齐验证
PFS
Fig. 1 a Centrally assessed PFS. b Investigator-assessed PFS. c Forest plot analysis of centrally assessed PFS. CAPOX capecitabine plus oxaliplatin, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, eCRF electronic case report form, HR hazard ratio, IWRS interactive web response system, n/c not countable, PD-L1 programmed death ligand 1, PFS progression-free survival, SOX S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T18:37:47+00:00 |